ArticleJAC-antimicrobial resistance2025
Comparative study of common over-the-counter wound care products against early and mature biofilms of antibiotic-resistant wound pathogens.
Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background: The global rise of antimicrobial resistance requires innovative and affordable wound care solutions. Moreover, managing wounds infected with priority pathogens remains a challenge. Despite the widespread availability of over-the-counter (OTC) antiseptics in wound care, comparative studies on their efficacy against biofilms or multidrug-resistant pathogens are limited. Objectives: This study compares the ability of different OTC antiseptics to disrupt biofilms of multidrug-resistant clinical isolates of Methods: The antimicrobial activity of seven antiseptics (polyhexanide, octenidine, chloroxylenol, chlorhexidine, ethanol, cetrimide, phenol) against early-stage (3-hour) and mature (24-hour) biofilms was determined by measuring reductions in colony-forming units (cfu)/biofilm while varying treatment exposure time. Results: All OTC products significantly reduced early-stage biofilms of both pathogens below detectable limits within 5 minutes ( Conclusion: OTC antiseptics are effective in eliminating early-stage biofilms; however, mature biofilms require either prolonged exposure, which may increase their toxicity and delay wound healing, or the use of potent formulations. Chlorhexidine gluconate, chloroxylenol and phenol offer an optimal balance between antibiofilm potency and tissue safety, offering promise for acute and chronic wound management particularly in low-resource settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.